Nanocarriers for treatment of ocular neovascularization in the back of the eye: New vehicles for ophthalmic drug delivery

Nanomedicine

Volumn 10, Issue 13, 2015, Pages 2093-2107

  Shen, Hsin Hui ^a   Chan, Elsa C ^b   Lee, Jia Hui ^b   Bee, Youn Shen ^c,d,e   Lin, Tsung Wu ^f   Dusting, Gregory J ^b   Liu, Guei Sheung ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d Yuh Ing Junior College of Health Care and Management   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

drug delivery; eye; nanocarriers; ocular neovascularization

Indexed keywords

DENDRIMER; DRUG VEHICLE; GOLD NANOPARTICLE; METAL NANOPARTICLE; NANOCARRIER; NANOPARTICLE; SILICA NANOPARTICLE; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; VASCULOTROPIN; DRUG; DRUG CARRIER; EYE DROPS;

DRUG DELIVERY SYSTEM; HUMAN; IMPLANT DELIVERY DEVICE; MICELLE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; EYE; NANOTECHNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; ULTRASTRUCTURE; VASCULARIZATION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS;

EID: 84937485036     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.47     Document Type: Review

References (82)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 10(2), 133-140 (2007).
2. Adamis AP, Aiello LP, D'amato RA. Angiogenesis and ophthalmic disease. Angiogenesis 3(1), 9-14 (1999).
3. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog. Retin. Eye Res. 36, 172-198 (2013).
4. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 15(23), 2724-2750 (2009).
5. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57(14), 2010-2032 (2005).
6. Gopinath B, Baur LA, Wang JJ et al. Smaller birth size is associated with narrower retinal arterioles in early adolescence. Microcirculation 17(8), 660-668 (2010).
7. Truong A, Wong TY, Khachigian LM. Emerging therapeutic approaches in the management of retinal angiogenesis and edema. J. Mol. Med. (Berl.) 89(4), 343-361 (2011).
8. Campochiaro PA. Ocular neovascularization. J. Mol. Med. (Berl.) 91(3), 311-321 (2013).
9. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 376(9735), 124-136 (2010).
10. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116(9), 1599-1603 (2009).
11. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120(1), 106-114 (2013).
12. Curcio CA, Johnson M. Structure, function, and pathology of bruch's membrane. Elastic 146(152), 210-213 (2012).
13. Cheung CM, Wong TY. Treatment of age-related macular degeneration. Lancet 382(9900), 1230-1232 (2013).
14. Wong TY, Ohno-Matsui K, Leveziel N et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br. J. Ophthalmol. 99(3), 289-296 (2014).
15. Thakur SS, Barnett NL, Donaldson MJ, Parekh HS. Intravitreal drug delivery in retinal disease: are we out of our depth? Expert Opin. Drug Deliv. 11(10), 1575-1590 (2014).
16. Wang X, Sawada T, Kakinoki M et al. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 252(7), 1033-1039 (2014).
17. Avery RL, Castellarin AA, Steinle NC et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98(12), 1636-1641 (2014).
18. Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5), 831-839 (2011).
19. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 4, 27 (2014).
20. Israelachvili JN, Mitchell DJ, Ninham BW. Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J. Chem. Society-Faraday Transactions II 72, 1525-1568 (1976).
21. Tanford C. The Hydrophobic Effects: Formation Of Micelles And Biological Membranes. Wiley, NY, USA (1980).
22. Yaghmur A, De Campo L, Sagalowicz L, Leser ME, Glatter O. Emulsified microemulsions and oil-containing liquid crystalline phases. Langmuir 21(2), 569-577 (2005).
23. Sagalowicz L, Leser ME, Watzke HJ, Michel M. Monoglyceride self-assembly structures as delivery vehicles. Trends Food Sci. Technol. 17(5), 204-214 (2006).
24. Konopka K, Lima MCPD, Simões S, Rossi JJ, Düzgünes N. Delivery of novel macromolecular drugs against HIV-1. Expert Opin. Biol. Ther. 1(6), 949-970 (2001).
25. Hamilton A, Biganzoli L, Coleman R et al. EORTC 10968: a Phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann. Oncol. 13(6), 910-918 (2002).
26. Grayson LS, Hansbrough JF, Zapata-Sirvent RL, Kim T, Kim S. Pharmacokinetics of DepoFoam gentamicin delivery system and effect on soft tissue infection. J. Surg. Res. 55(5), 559-564 (1993).
27. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
28. Rajala A, Wang Y, Zhu Y et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 14(9), 5257-5263 (2014).
29. Li X, Zhang Z, Li J, Sun S, Weng Y, Chen H. Diclofenac/ biodegradable polymer micelles for ocular applications. Nanoscale 4(15), 4667-4673 (2012).
30. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano 6(9), 7595-7606 (2012).
31. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1(3), 325-327 (2005).
32. Skirtach AG, Javier AM, Kreft O et al. Laser-induced release of encapsulated materials inside living cells. Angew. Chem. Int. Ed. Engl. 45(28), 4612-4617 (2006).
33. Kim JH, Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 20(50), 505101 (2009).
34. Ahamed M. Silica nanoparticles-induced cytotoxicity, oxidative stress and apoptosis in cultured A431 and A549 cells. Human Exp. Toxicol. 32(2), 186-195 (2013).
35. Vivero-Escoto JL, Slowing Ii, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6(18), 1952-1967 (2010).
36. Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60(11), 1278-1288 (2008).
37. Carpenter EE. Iron nanoparticles as potential magnetic carriers. J. Magn. Magnet. Mater. 225(1), 17-20 (2001).
38. Häfeli U. Magnetically modulated therapeutic systems. Int. J. Pharmaceut. 277(1), 19-24 (2004).
39. Pankhurst QA, Connolly J, Jones S, Dobson J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 36(13), R167 (2003).
40. Yanai A, Hafeli UO, Metcalfe AL et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant. 21(6), 1137-1148 (2012).
41. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drug delivery from ocular implants. Expert Opin. Drug Deliv. 3(2), 261-273 (2006).
42. Hsu J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol. 18(3), 235-239 (2007).
43. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2(1), 67-108 (1986).
44. Maurice DM. Drug delivery to the posterior segment from drops. Surv. Ophthalmol. 47(Suppl. 1), S41-S52 (2002).
45. Gan L, Wang J, Jiang M et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov. Today 18(5-6), 290-297 (2013).
46. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur. J. Ophthalmol. 21(Suppl. 6), S3-S9 (2011).
47. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16(5), 645-659 (2009).
48. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29(3), 313-318 (2009).
49. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Experiment. Ophthalmol. 29(1), 2-6 (2001).
50. Bourges JL, Gautier SE, Delie F et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44(8), 3562-3569 (2003).
51. Shelke NB, Kadam R, Tyagi P, Rao VR, Kompella UB. Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv. Transl. Res. 1(1), 76-90 (2011).
52. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1(1), 99-114 (2004).
53. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J. Ocul. Pharmacol. Ther. 20(1), 55-64 (2004).
54. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 57(12), 1555-1563 (2005).
55. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog. Retin. Eye Res. 17(1), 33-58 (1998).
56. Kim JH, Kim MH, Jo DH, Yu YS, Lee TG, Kim JH. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 32(7), 1865-1871 (2011).
57. Cho WK, Kang S, Choi H, Rho CR. Topically administered gold nanoparticles inhibit experimental corneal neovascularization in mice. Cornea 34(4), 456-459 (2015).
58. Kalishwaralal K, Banumathi E, Ram Kumar Pandian S et al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf. B Biointerfaces 73(1), 51-57 (2009).
59. Kalishwaralal K, Barathmanikanth S, Pandian SR, Deepak V, Gurunathan S. Silver nano-a trove for retinal therapies. J. Control. Release 145(2), 76-90 (2010).
60. Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials 30(31), 6341-6350 (2009).
61. Jo DH, Kim JH, Yu YS, Lee TG, Kim JH. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomedicine 8(5), 784-791 (2012).
62. Gross N, Ranjbar M, Evers C et al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol. Vis. 19, 54-61 (2013).
63. Kim H, Choi JS, Kim KS, Yang JA, Joo CK, Hahn SK. Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta Biomaterialia 8(11), 3932-3940 (2012).
64. Park K, Chen Y, Hu Y et al. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemiainduced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 58(8), 1902-1913 (2009).
65. Iriyama A, Oba M, Ishii T et al. Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivo. PLoS ONE 6(12), e28560 (2011).
66. Di Tommaso C, Bourges JL, Valamanesh F et al. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur. J. Pharm. Biopharm. 81(2), 257-264 (2012).
67. Shmueli RB, Ohnaka M, Miki A et al. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials 34(30), 7544-7551 (2013).
68. Iwase T, Fu J, Yoshida T et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J. Control. Release 172(3), 625-633 (2013).
69. Xu J, Wang Y, Li Y et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laserinduced rat model. J. Ocul. Pharmacol. Ther. 23(6), 527-540 (2007).
70. Luo L, Zhang X, Hirano Y et al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 7(4), 3264-3275 (2013).
71. Wang Z, Cheng R, Lee K et al. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler. Thromb. Vasc. Biol. 35(4), 855-864 (2015).
72. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Agerelated macular degeneration. Lancet 379(9827), 1728-1738 (2012).
73. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N. Engl. J. Med. 363(22), 2135-2144 (2010).
74. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 4(4), 297-305 (2007).
75. Wei L, Cai C, Lin J, Chen T. Dual-drug delivery system based on hydrogel/micelle composites. Biomaterials 30(13), 2606-2613 (2009).
76. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv. 7(1), 49-62 (2010).
77. Lin WS, Huang YW, Zhou XD, Ma YF. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol. Appl. Pharmacol. 217(3), 252-259 (2006).
78. Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J. Am. Chem. Soc. 132(13), 4834-4842 (2010).
79. Harris L, Goff J, Carmichael A et al. Magnetite nanoparticle dispersions stabilized with triblock copolymers. Chem. Mater. 15(6), 1367-1377 (2003).
80. Santra S, Tapec R, Theodoropoulou N, Dobson J, Hebard A, Tan W. Synthesis and characterization of silica-coated iron oxide nanoparticles in microemulsion: the effect of nonionic surfactants. Langmuir 17(10), 2900-2906 (2001).
81. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther. 20(1), 43-53 (2004).
82. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J. Ocul. Pharmacol. Ther. 17(6), 565-572 (2001).